Teva Pharma (TEVA) Cut to Junk by S&P; to BB/Stable from BBB-/Watch
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharma (NYSE: TEVA) Cut to Junk at S&P; to BB/Stable from BBB-/Watch
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Reiterates Buy Rating on Teva Pharma (TEVA) as Pipeline Opportunities Broaden
- International Paper to close four facilities by end of Q3 2026
- FDA approves AbbVie's Skyrizi for children with psoriatic disease
Create E-mail Alert Related Categories
Corporate News, Credit RatingsRelated Entities
Standard & Poor'sSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
